Multiple myeloma pathogenesis is marked by incredibly complex processes that range beyond primary or acquired genetic alterations, with factors in the ...

In patients with multiple myeloma (MM), serum concentration of chitinase 3-like protein-1 (CHI3L1) protein is correlated with disease severity and predicts disease progression, according to research ...

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple ...

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple ...

Multiple myeloma (MM) is characterized by a significant heterogeneity at the molecular level. The first level is the chromosomal one. Although cytogenetics is difficult to assess in MM, patients can ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.

Signaling pathways in the pathogenesis of multiple myeloma. Signaling pathways such as PI3K/AKT/mTOR, JAK/STAT, RAS/MAPK, Wnt/β-catenin and NF-κB pathway participate the pathogenesis of MM by ...

A new review published in Molecular Biomedicine sheds light on the intricate signaling pathways involved in multiple myeloma (MM) and the exciting advances in targeted therapies. The authors delve ...

Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are “hideously expensive,” Dr. June said, costing more than $100,000 a year.